Last December, the company raised its quarterly payout for the 16th consecutive year. The dividend yield investors could ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Markets today face key jobs data, fresh U.S. tariffs, and earnings from Wendy’s, AMC Networks, and other midcaps ahead of the ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Natural gas futures rise on heat-driven demand. Traders await today’s storage report and watch $3.301 resistance for bullish ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

The government is in talks with pharmaceutical companies to raise the prices of certain medications outside the U.S.

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...